english.prescrire.org > Spotlight > 100 most recent > Management of conflicts of interest at the EMA: are drug evaluations really shielded from industry influence?

Spotlight

Every month, the subjects in Prescrire’s Spotlight.

100 most recent :  1 | 10 | 20 | 30 | 40 | 50 | 60 | 70 | 80 | 90

Management of conflicts of interest at the EMA: are drug evaluations really shielded from industry influence?

 Queries and Comments  In response to an editorial published in Prescrire International in June 2025, on the management of conflicts of interest at the European Medicines Agency (EMA), we received a letter from the EMA's Head of Public and Stakeholders Engagement Department, Juan Garcia Burgos. We have published this letter and our response in this article.
Full article available for download (FREE)

 ©Prescrire 1 April 2026

Source: "Management of conflicts of interest at the EMA: are drug evaluations really shielded from industry influence?" Prescrire Int 2026; 35 (280): 110-111. FREE.

Filet

Enjoy full access to Prescrire International, and support independent information

 
Share
Share on Facebook  
 
 
See also:
 
"Management of conflicts
of interest at the EMA:
chronic failure"
Prescrire Int 2025;
34 (271): 143.
FREE
 
"Revolving door between
the public and private
sectors: conflict of interest"
Prescrire Int 2023;
32 (244): 3.
FREE